Abstract
A representative percentage of the medicines manufactured in Brazil is based on expired patent drugs. As the generic drugs market is becoming more competitive and less profitable, incremental innovation is a strategic alternative to survive long term. Our purpose was to identify factors that influence the investment in innovation on patent-expired medicines (PEM) by pharmaceutical laboratories installed in Brazil. We also aimed to propose a theoretical model that would be helpful to understand the innovation process on PEM, main components, influencing factors and their relationships. Data from the market were collected by interviewing experts and executives from the pharmaceutical companies installed in Brazil. The empirical data were analyzed in respect to the proposed theoretical model. We found out that in order to invest in incremental innovations on expired patent drugs it is necessary to develop an appropriate business model to market the new product, which is quite different from the former structure used to generic drugs. We also identified that one of the main difficulties is related to the required professional capabilities for producing the innovations. A case of success is presented as an example of investment in incremental innovation on PEM in Brazil.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
